0I5RCytRx Corporation
Data unavailable—Mkt Cap: —P/E: —133d ago
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a …
Industry Peers
Biotechnology$133.74BUSDP/E 30.8
$78.76BUSD
$77.45BUSDP/E 18.6
$60.46BUSDP/E 37.0
$57.09BUSDP/E 36.6
$44.04BUSDP/E 18.8
$43.24BUSD
$41.52BUSDP/E 65.7
$34.17BUSDP/E 44.6
$33.73BUSDP/E 31.4
$26.71BUSD
$25.70BUSD
$25.30BUSDP/E 15.9
$24.89BUSD
$21.74BUSDP/E 28.1
$20.62BUSDP/E 27.7
$15.47BUSDP/E 16.3
$15.13BUSDP/E 18.1
$14.46BUSDP/E 18.4
$13.02BUSD
Key Statistics
Company
Market Cap—
Enterprise Value-157.44K $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-2.50M $
Revenue/Share—
Last Price—
Fiscal Year EndDec 2024
MR QuarterMar 2025
Employees2
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA0.04
EV/Revenue—
P/S—
P/B-0.02
EPS (TTM)-0.35
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA-176.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.86M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-206.95K $
Net Debt/EBITDA0.06
Balance Sheet
Debt/Equity—
Current Ratio0.11
Quick Ratio0.09
Book Value/Sh-4.3120 USD
Cash/Share0.4180 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.01:1
Split DateMay 17, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.33.64M
Float491.71K
Insiders0.68%
Institutions0.00%
Technical
SMA 502.017 USD
SMA 2002.017 USD
Beta1.30
S&P 52W Chg16.25%
Avg Vol (30d)—
Avg Vol (10d)427
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—